Current Report Filing (8-k)
November 04 2016 - 4:08PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): October 31, 2016
Carbylan Therapeutics, Inc.
(Exact name of Registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36830
|
|
20-0915291
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification Number)
|
39899 Balentine Drive, Suite 200
Newark, California 94560
(Address of principal executive offices)
(510)
933-8365
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to
Rule 14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement communications pursuant to
Rule 14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to
Rule 13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
On October 31, 2016, the Superior Court of the State of California in and for the
County of Alameda (the
Court
) approved a voluntary dismissal of the purported stockholder class action complaint filed in the Court on September 26, 2016 against certain members of the board of directors and certain
executives of Carbylan Therapeutics, Inc., as well as against KalVista Pharmaceuticals Ltd., Wedbush Securities Inc. and certain unknown employees of Wedbush, entitled
Laidlaw v. Carbylan Therapeutics, Inc., et al.
, Case No. RG16832665.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
CARBYLAN THERAPEUTICS, INC.
|
|
|
|
|
Date: November 4, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ David M. Renzi
|
|
|
|
|
Name:
|
|
David M. Renzi
|
|
|
|
|
Title:
|
|
President and Chief Executive Officer
|
CARBYLAN THERAPEUTICS, INC. (NASDAQ:CBYL)
Historical Stock Chart
From Apr 2024 to May 2024
CARBYLAN THERAPEUTICS, INC. (NASDAQ:CBYL)
Historical Stock Chart
From May 2023 to May 2024